Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

NRC Health (NRC) SEC Filings & Earnings Calls

EquiReason read 19 NRC Health SEC filings in the last 12 months. Latest: 8-K on 2026-10-19 — CEO Trent Green appointed as interim principal financial officer; no compensation changes; no arrangements or understandings disclosed..

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

NRCNRC HealthFollow NRC — free
Health Information Services · Healthcare
—
Price chart with a free account
Market cap
485.1M
P/E TTM
88.9
Dividend yield
2.7%
52-week
—
Next earnings
3 Nov, in 10 days

Every filing, read

last 12 months · SEC

What happened, the numbers inside, guidance and risks. The original is one click away.

19 Oct 20268-K · 5.02CEO Trent Green appointed as interim principal financial officer; no compensation changes; no arrangements or understandings disclosed.open

Risks flagged

CEO dual role may indicate temporary leadership gap in finance function.

“CEO appointed as interim principal financial officer; no permanent CFO named.”
Read the original on SEC EDGAR ↗
11 Aug 20268-K · 5.02Reported a director or officer change (departure, election, appointment or pay arrangement)open

Risks flagged

CFO departure may disrupt financial operations and investor confidence

“CFO resignation effective Aug 28, 2026; search for replacement initiated.”
Read the original on SEC EDGAR ↗
4 Aug 202610-QNRC Health reported Q2 2026 results with 4% revenue growth and 11% TRCV growth, but operating income swung to a loss due to $7.1M in stock-based compensation related to executive leadership. Adjusted net income grew 7% YoY.earningsopen

Figures in the filing · each found in the filing text

Revenue · Q2-2026$35M+4% y/y
Net income (loss) · Q2-2026$-3M
Adjusted EBITDA · Q2-2026$9M-8% y/y
Total Recurring Contract Value (TRCV) · 2026-06-30$152M+11% y/y
Operating cash flow · 6M-2026$9M+56% y/y
Free cash flow · 6M-2026$5M
Capital expenditures · 6M-2026$3M-47% y/y

Risks flagged

Executive compensation overhang

“Selling, general, and administrative expenses increased to $22.9 million for the 2026 period, from $17.7 million for the same period in 2025. The increase was primarily driven by $7.1 million of higher stock-based compensation expense related to executive leadership.” · word for word

Operating loss

“Operating income (loss) $(3,238) in Q2 2026 vs $1,588 in Q2 2025.”
Read the original on SEC EDGAR ↗
28 Jul 20268-K · 2.02Total Recurring Contract Value (TRCV) $152M (+11% y/y); Revenue $35M (+4% y/y); GAAP Net Loss $-3Mearningsopen

Figures in the filing · each found in the filing text

Total Recurring Contract Value (TRCV) · Q2-2026$152M+11% y/y
Revenue · Q2-2026$35M+4% y/y
GAAP Net Loss · Q2-2026$-3M
Adjusted Net Income · Q2-2026$7M
Adjusted EBITDA · Q2-2026$9M
Free Cash Flow · Q2-2026$100000.00
Operating Cash Flow · Q2-2026$1M
GAAP Net Loss Per Diluted Share · Q2-2026$-0.15
Adjusted Net Income Per Diluted Share · Q2-2026$0.31

Risks flagged

GAAP net loss and low free cash flow due to one-time adjustment items

“GAAP net loss ($3.3M); free cash flow $0.1M reflecting $2.9M cash payment for Adjustment Items”
Read the original on SEC EDGAR ↗
12 Jun 2026SC 13D/AAmendment No. 4 to Schedule 13D for NRC Health discloses open-market sales of 250,000 shares by an irrevocable trust and a 20,000-share gift by a charitable foundation, with no change in control intent.SEC ↗
12 Jun 2026SC 13D/AAmendment No. 4 to Schedule 13D for NRC Health discloses open-market sales of 250,000 shares by an irrevocable trust and a 20,000-share gift by a charitable foundation, with no change in control intent.SEC ↗
8 May 2026DEF 14ANRC Health filed its 2026 proxy statement (DEF 14A) with proposals to declassify the board, remove supermajority voting requirements, and approve executive compensation.open

Figures in the filing · each found in the filing text

Revenue · FY2025$137M
Net Income · FY2025$12M

Risks flagged

Insider ownership concentration risk

“As of March 31, 2026, approximately 38.2% of our outstanding common stock was held by the Common Property Trust (the “Trust”), the principal holder of shares previously owned by Mr. Hays, and approximately 47.6% of our outstanding common stock was held by the Trust and other entities controlled by trustees or special power holders for the benefit of members ” · word for word
Read the original on SEC EDGAR ↗
6 May 202610-QRevenue $35M (+4% y/y); Net income $3M (-44% y/y); Total Recurring Contract Value $152M (+13% y/y)open

Figures in the filing · each found in the filing text

Revenue · Q1-2026$35M+4% y/y
Net income · Q1-2026$3M-44% y/y
Total Recurring Contract Value · 2026-03-31$152M+13% y/y
Operating margin · Q1-202616.0%
Adjusted EBITDA · Q1-2026$9M-9% y/y
Free cash flow · Q1-2026$5M+46% y/y
Operating cash flow · Q1-2026$7M+8% y/y

Risks flagged

Executive transition costs

“The increase was primarily driven by $1.4 million of higher stock‑based compensation related to executive leadership and approximately $0.5 million of executive salary expense that was not present in the prior‑year period.” · word for word

One-time compensation charges

“The amendments and related bonuses are expected to result in approximately $9.4 million of expense during the second quarter of 2026.” · word for word
Read the original on SEC EDGAR ↗
28 Apr 20268-K · 5.02Reported a director or officer change (departure, election, appointment or pay arrangement)open

Risks flagged

One-time expense may impact earnings, but non-cash portion accelerates future expense.

“consisting of (i) approximately $6.5 million of non-cash accelerated equity compensation expense... and (ii) approximately $2.9 million of cash bonus expense.”
Read the original on SEC EDGAR ↗
28 Apr 202610-K/ARevenue $137M; Net Income $12Mopen

Figures in the filing · each found in the filing text

Revenue · FY2025$137M
Net Income · FY2025$12M
Read the original on SEC EDGAR ↗
28 Apr 20268-K · 2.02NRC Health Q1 2026: Revenue $34.8M (+4% YoY); TRCV $152.1M (+13%); Adj EBITDA $9.4M (27% margin); first YoY revenue growth since 2023; largest deal in history.earningsopen

Figures in the filing · each found in the filing text

Revenue · Q1-2026$35M+4% y/y
Total Recurring Contract Value (TRCV) · Q1-2026$152M+13% y/y
Adjusted EBITDA · Q1-2026$9M
GAAP Diluted EPS · Q1-2026$0.14-44% y/y
Adjusted Diluted EPS · Q1-2026$0.21
Operating Cash Flow · Q1-2026$7M+8% y/y
Free Cash Flow · Q1-2026$5M
Operating Income · Q1-2026$6M-35% y/y

Risks flagged

GAAP net income declined 44% YoY due to higher SG&A and interest expense

“Net income $3.2M vs $5.8M YoY; SG&A $13.4M vs $10.4M; interest expense $1.3M vs $0.9M”
Read the original on SEC EDGAR ↗
20 Apr 20268-K · 5.02, 5.03Reported the departure of a director or principal officer (CEO/CFO change); amended its articles of incorporation or bylawsSEC ↗
27 Mar 2026SC 13D/AFounder/Chairman Michael D. Hays's beneficial ownership dropped below 5% due to relinquishment of reacquisition rights over 582,688 shares held by irrevocable trusts.open

Figures in the filing · each found in the filing text

Total Recurring Contract Value · FY2026$170M
Read the original on SEC EDGAR ↗
27 Mar 2026SC 13D/ASchedule 13D/A: Common Property Trust 46.5%SEC ↗
5 Mar 20268-K · 7.01Total Recurring Contract Value (TRCV) $152M (+13% y/y)open

Figures in the filing · each found in the filing text

Total Recurring Contract Value (TRCV) · Q1-2026$152M+13% y/y
Read the original on SEC EDGAR ↗
5 Mar 202610-KFiling text is limited to forward-looking statements and business description boilerplate; no quantified operating or financial signals, no guidance, no material risk tied to current operations.SEC ↗
3 Feb 20268-K · 2.02Total Recurring Contract Value (TRCV) $144M (+8% y/y); Revenue $35M; GAAP Net Income $2Mearningsopen

Figures in the filing · each found in the filing text

Total Recurring Contract Value (TRCV) · Q4-2025$144M+8% y/y
Revenue · Q4-2025$35M
GAAP Net Income · Q4-2025$2M
Adjusted Net Income · Q4-2025$3M
Adjusted EBITDA · Q4-2025$9M
Operating Cash Flow · Q4-2025$7M+13% y/y
GAAP Net Income Per Diluted Share · Q4-2025$0.08
Adjusted Net Income Per Diluted Share · Q4-2025$0.16
Full Year Revenue · FY2025$137M
Full Year GAAP Net Income · FY2025$12M
Read the original on SEC EDGAR ↗
7 Nov 202510-QNRC Health reported Q3 2025 revenue of $34.6M (-3% YoY) and YTD revenue of $102.2M (-4% YoY), with operating margin stable at 22% in Q3 but down 600bps YTD to 18%. TRCV grew 8% YoY to $141.7M.earningsopen

Figures in the filing · each found in the filing text

Revenue · Q3-2025$35M-3% y/y
Revenue · 9M-2025$102M-4% y/y
Net Income · FY2025$12M
Total Recurring Contract Value · Q3-2025$142M+8% y/y
Operating Income · Q3-2025$8M-3% y/y
Operating Income · 9M-2025$18M-30% y/y
Cash provided by operating activities · 9M-2025$19M-32% y/y
Capital Expenditures · 9M-2025$10M

Risks flagged

Revenue decline from existing clients

“Revenue in the 2025 period decreased compared to the 2024 period by $1.2 million. This was mainly from decreased recurring revenue of $1.6 million in our existing client base” · word for word

High leverage and interest expense

“Total other expense increased in the 2025 period compared to the 2024 period primarily due to higher interest expense of $0.8 million mainly from higher borrowings outstanding on our Delayed Draw Term Loan” · word for word

Working capital deficit

“We had a working capital deficit of $18.2 million and $16.3 million on September 30, 2025 and December 31, 2024, respectively.” · word for word
Read the original on SEC EDGAR ↗
27 Oct 20258-K · 2.02Total Recurring Contract Value (TRCV) $142M (+8% y/y); Revenue $35M; GAAP Net Income $4Mearningsopen

Figures in the filing · each found in the filing text

Total Recurring Contract Value (TRCV) · Q3-2025$142M+8% y/y
Revenue · Q3-2025$35M
GAAP Net Income · Q3-2025$4M
Adjusted Net Income · Q3-2025$5M
Adjusted EBITDA · Q3-2025$11M+11% y/y
Operating Cash Flow · Q3-2025$14M+46% y/y
GAAP Net Income Per Diluted Share · Q3-2025$0.18
Adjusted Net Income Per Diluted Share · Q3-2025$0.23
Read the original on SEC EDGAR ↗

NRC Health — questions

What did NRC Health file recently?
19 SEC filings in the last 12 months. Latest: 8-K on 2026-10-19 — CEO Trent Green appointed as interim principal financial officer; no compensation changes; no arrangements or understandings disclosed.

Every figure on this page comes from NRC Health's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.